Should you lie to your granny?When it comes to healthcare there are different opinions about patient care east and west, and as market Share XShould you lie to your granny?https://pharmaphorum.com/views-and-analysis/should-you-lie-to-your-granny-healthcare/
Navigating emerging markets – opportunities and challenges for pharmaThe pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of Share XNavigating emerging markets – opportunities and challenges for pharmahttps://pharmaphorum.com/views-analysis-market-access/navigating-emerging-markets-opportunities-and-challenges-for-pharma/
Humanising healthcare through technologyAn early exposure to computer science by way of the Commodore 64, combined with subsequent medical studies, set Share XHumanising healthcare through technologyhttps://deep-dive.pharmaphorum.com/magazine/sales-and-marketing-2019/humanising-healthcare-through-technology/
Comms from the ground upDavid Hunt’s career has taken him from painting Havas Lynx Group’s offices to running the agency, and now Share XComms from the ground uphttps://deep-dive.pharmaphorum.com/magazine/sales-and-marketing-2019/comms-from-the-ground-up-david-hunt-havas/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Bridging the gap between industry and charities: Enabling PPI in researchPublic and patient involvement (PPI) in clinical research is the new normal, but bridging the gap between how Share XBridging the gap between industry and charities: Enabling PPI in researchhttps://pharmaphorum.com/views-analysis-patients/bridging-the-gap-between-industry-and-charities-enabling-ppi-in-research/
A new breed of pharma manufacturingOver the last few years the effect of Brexit’s political instability on our industry has been inescapable as Share XA new breed of pharma manufacturinghttps://pharmaphorum.com/r-d/views-analysis-r-d/a-new-breed-of-pharma-manufacturing/
Biosimilars in the UK: where are we now and where does the NHS want to go?The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges Share XBiosimilars in the UK: where are we now and where does the NHS want to go?https://pharmaphorum.com/views-analysis-market-access/biosimilars-in-the-uk/
A pharma guide to digital health, multichannel and digital transformationPaul Tunnah runs through the six key aspects of digital health and how businesses can harness them. It’s that Share XA pharma guide to digital health, multichannel and digital transformationhttps://pharmaphorum.com/views-analysis-sales-marketing/a-pharma-guide-to-digital-health-multichannel-and-digital-transformation/
